HBV感染免疫耐受期患者应进行抗病毒治疗降低病毒量

林炳亮

doi:10.3969/j.issn.1001-5256.2021.04.009

HBV感染免疫耐受期患者应进行抗病毒治疗降低病毒量

DOI: 10.3969/j.issn.1001-5256.2021.04.009

林炳亮

中山大学附属第三医院感染科，广州 510630

详细信息

作者简介:
林炳亮(1968—)，男，医学博士，科副主任，主要从事病毒性肝炎防治、终末期肝病救治方面的研究

中图分类号: R512.62
计量
- 文章访问数: 350
- HTML全文浏览量: 123
- PDF下载量: 73
- 被引次数: 0
出版历程
- 收稿日期: 2021-02-20
- 录用日期: 2021-02-28
- 出版日期: 2021-04-20

Patients in the immune-tolerant phase of hepatitis B virus infection should receive antiviral therapy to reduce viral load

Bingliang LIN

Department of Infectious Diseases, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510630, China

摘要

- 乙型肝炎病毒 /
- 乙型肝炎，慢性 /
- 免疫耐受 /
- 治疗学
- Hepatitis B virus /
- Hepatitis B, Chronic /
- Immune Tolerance /
- Therapeutics

HTML全文

参考文献(21)

[1]	Chinese Society of Infectious Diseases, Chinese Medical Association; Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007. 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
[2]	SARIN SK, KUMAR M, LAU GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: A 2015 update[J]. Hepatol Int, 2016, 10(1): 1-98. DOI: 10.1007/s12072-015-9675-4.
[3]	European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2017, 67(2): 370-398. DOI: 10.1016/j.jhep.2017.03.021.
[4]	TERRAULT NA, LOK A, MCMAHON BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. Hepatology, 2018, 67(4): 1560-1599. DOI: 10.1002/hep.29800.
[5]	NGUYEN MH, GARCIA RT, TRINH HN, et al. Histological disease in Asian-Americans with chronic hepatitis B, high hepatitis B virus DNA, and normal alanine aminotransferase levels[J]. Am J Gastroenterol, 2009, 104(9): 2206-2213. DOI: 10.1038/ajg.2009.248.
[6]	CHEN J, XU CR, XI M, et al. Predictors of liver histological changes and a sustained virological response to peginterferon among chronic hepatitis B e antigen-positive patients with normal or minimally elevated alanine aminotransferase levels[J]. J Viral Hepat, 2017, 24(7): 573-579. DOI: 10.1111/jvh.12679.
[7]	MILICH DR, JONES JE, HUGHES JL, et al. Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero?[J]. Proc Natl Acad Sci U S A, 1990, 87(17): 6599-6603. DOI: 10.1073/pnas.87.17.6599.
[8]	TIAN Y, KUO CF, AKBARI O, et al. Maternal-derived hepatitis B virus e antigen alters macrophage function in offspring to drive viral persistence after vertical transmission[J]. Immunity, 2016, 44(5): 1204-1214. DOI: 10.1016/j.immuni.2016.04.008.
[9]	HONG M, SANDALOVA E, LOW D, et al. Trained immunity in newborn infants of HBV-infected mothers[J]. Nat Commun, 2015, 6: 6588. DOI: 10.1038/ncomms7588.
[10]	VANWOLLEGHEM T, HOU J, VAN OORD G, et al. Re-evaluation of hepatitis B virus clinical phases by systems biology identifies unappreciated roles for the innate immune response and B cells[J]. Hepatology, 2015, 62(1): 87-100. DOI: 10.1002/hep.27805.
[11]	BERTOLETTI A, FERRARI C. Adaptive immunity in HBV infection[J]. J Hepatol, 2016, 64(1 Suppl): s71-s83. DOI: 10.1016/j.jhep.2016.01.026.
[12]	KENNEDY P, SANDALOVA E, JO J, et al. Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B[J]. Gastroenterology, 2012, 143(3): 637-645. DOI: 10.1053/j.gastro.2012.06.009.
[13]	PARK JJ, WONG DK, WAHED AS, et al. Hepatitis B virus-specific and global T-cell dysfunction in chronic hepatitis B[J]. Gastroenterology, 2016, 150(3): 684-695.e5. DOI: 10.1053/j.gastro.2015.11.050.
[14]	CHEN CJ, YANG HI, SU J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level[J]. JAMA, 2006, 295(1): 65-73. DOI: 10.1001/jama.295.1.65.
[15]	LIAW YF, SUNG JJ, CHOW WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease[J]. N Engl J Med, 2004, 351(15): 1521-1531. DOI: 10.1056/NEJMoa033364.
[16]	CHANG Y, CHOE WH, SINN DH, et al. Nucleos(t)ide analogue treatment for adult patients with HBeAg-positive chronic infection with genotype C hepatitis B virus: A nationwide real-life study[J]. J Infect Dis, 2017, 26(11): 1407-1414. DOI: 10.1093/infdis/jix506.
[17]	PARK JY, PARK YN, KIM DY, et al. High prevalence of significant histology in asymptomatic chronic hepatitis B patients with genotype C and high serum HBV DNA levels[J]. J Viral Hepat, 2008, 15(8): 615-621. DOI: 10.1111/j.1365-2893.2008.00989.x.
[18]	MASON WS, GILL US, LITWIN S, et al. HBV DNA integration and clonal hepatocyte expansion in chronic hepatitis B patients considered immune tolerant[J]. Gastroenterology, 2016, 151(5): 986-998.e4. DOI: 10.1053/j.gastro.2016.07.012.
[19]	BILL CA, SUMMERS J. Genomic DNA double-strand breaks are targets for hepadnaviral DNA integration[J]. Proc Natl Acad Sci U S A, 2004, 101(30): 11135-11140. DOI: 10.1073/pnas.0403925101.
[20]	KIM GA, LIM YS, HAN S, et al. High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B[J]. Gut, 2018, 67(5): 945-952. DOI: 10.1136/gutjnl-2017-314904.
[21]	LEE HW, KIM SU, OIDOV B, et al. Comparison between chronic hepatitis B patients with untreated immune-tolerant phase vs those with virological response by antivirals[J]. Sci Rep, 2019, 9(1): 2508. DOI: 10.1038/s41598-019-39043-2.